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Objectives: To determine whether statin treatment is
associated with increased risk of haemorrhagic stroke
(HS) in older women. A secondary objective was to
evaluate HS risk in users of combined statin and
antiplatelet treatment.
Design: Observational study: secondary data analysis
from the Women’s Health Initiative (WHI) clinical trials.
Setting:Women were recruited from 40 participating
sites.
Participants: Cohort of 68 132 women followed
through 2005 (parent study) and for an additional
5 years in the extension study.
Main outcome measures: Statin use was assessed at
baseline and at follow-up visits (1, 3, 6 and 9 years).
Women brought medications in original containers for
inventory. Strokes were ascertained semiannually and
centrally adjudicated. Risk of HS by statin use (time-
varying covariate, with the ‘no use’ category as the
referent) was estimated from Cox proportional hazard
regression models adjusted for age (model 1); risk
factors for HS (model 2); and possible confounders by
indication (model 3). Prespecified subgroup analyses
were conducted by use of antiplatelet medications.
Results: Final models included 67 882 women (mean
age, 63±7 years). Over a mean follow-up of 12 years,
incidence rates of HS were 6.4/10 000 person-years
among statin users and 5.0/10 000 person-years among
non-users (p=0.11). The unadjusted risk of HS in statin
users was 1.21 (CI 0.96 to 1.53); after adjusting for age
and HS risk factors the HR was 0.98 (CI 0.76 to 1.26).
Risk of HS was higher among women on statins and
antiplatelet agents versus women on antiplatelet
medications alone (HR=1.59; CI 1.03 to 2.47); p for
interaction=0.011.
Conclusions: This retrospective analysis did not show
an association between statin use and HS risk among
older women. HS risk was higher among women taking
statins with antiplatelet agents. These findings warrant
further investigation, given potential implications for
clinical decision-making.
BACKGROUND
Based on a number of randomised clinical
trials that have established the efficacy of
statins in the primary and secondary preven-
tion of cardiovascular events,1 statin therapy
is widely recommended for the treatment of
hypercholesterolaemia and for the preven-
tion of cardiovascular events.2 The imple-
mentation of the most recent guidelines on
the treatment of blood cholesterol, however,
may result in a number of individuals receiv-
ing statins that may reach up to one billion
worldwide.3 Given the potential for
large-scale ‘statinisation’ concerns about
safety become more compelling.3
Consistent with the evidence from observa-
tional studies of an inverse association
between plasma cholesterol levels and risk of
intracerebral haemorrhage,4–7 some studies
have reported an excess of haemorrhagic
strokes (HSs) in patients treated with statins,
Strengths and limitations of this study
▪ Use of a large cohort of older female participants
for which there is limited information on the
association between statin use and haemorrhagic
stroke (HS) and whether use of combined treat-
ment with statin and antiplatelet medications
poses additional risk.
▪ Long duration of follow-up and excellent adjudi-
cation of HS.
▪ Lack of plasma low-density lipoprotein (LDL)
cholesterol data does not allow assessment of
whether HS was associated with lower LDL
levels.
▪ Analysis conducted among a cohort of older
women enrolled in the Women’s Health Initiative
Clinical Trials, limiting generalisability.
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particularly among individuals with a previous stroke.8–12
A meta-analysis of large randomised clinical trials of
statin (or more statin) versus controls (or less statin)
showed that statin treatment, compared with no statin,
was associated with a 15% reduction in the overall risk
of stroke which was largely driven by a reduction in the
risk of ischaemic stroke, while there was a non-significant
increase in the risk of HS (risk ratio (RR)=1.15; CI 0.93
to 1.41). A recent meta-analysis from the same group
has confirmed a non-significant increase in the risk of
HS (HR=1.15; CI 0.97 to 1.38 per 1.0 mmol/L reduction
in low-density lipoprotein (LDL) cholesterol) among
participants receiving statin treatment or a higher statin
dose compared with those receiving no statin or a lower
statin dose. However, only about 30% of participants in
these trials were female and the median follow-up was
5 years.1
The primary aim of this analysis was to evaluate
whether statin treatment is associated with an increased
risk of HS in a female cohort of community-dwelling
women enrolled in the Women’s Health Initiative (WHI).
This study has several important advantages: a large
female population, a long follow-up duration (mean,
12 years) and the adjudication of all cerebrovascular
events. In addition, since statins and antiplatelet agents
are both recommended for the secondary prevention of
cardiovascular disease and are frequently prescribed
together in clinical practice, we evaluated whether
women on statins who received concurrent treatment
with antiplatelets medication were at increased risk.
METHODS
Design and population
The WHI included a set of randomised clinical trials and
a separate observational study.13 The present study is a
secondary analysis of 68 132 women enrolled in the WHI
clinical trials. Women enrolled in the observational study
were not considered for this analysis because in this sub-
cohort information about statin use was collected only at
baseline and year 3 of follow-up. The clinical trials
included randomised trials on hormone replacement
therapy, diet modification and a calcium and vitamin D
trial. To be eligible, women had to be 50–79 years old,
postmenopausal and plan to reside in the study recruit-
ment area for at least 3 years following enrolment.
Exclusion criteria were medical conditions predictive of a
survival time of less than 3 years, conditions inconsistent
with study participation and adherence such as alcohol-
ism, drug dependency, mental illness or dementia, and
enrolment in another clinical trial. In addition, women
were excluded from participation in the clinical trials for
(1) reasons related to competing risk (invasive cancer in
the past 10 years, breast cancer at any time or suspicion
of breast cancer at baseline screening, acute myocardial
infarction, stroke, or transient ischaemic attack (TIA) in
the previous 6 months, known chronic active hepatitis or
severe cirrhosis); (2) safety reasons (blood counts
indicative of disease, severe hypertension or currently use
of oral corticosteroids); (3) reasons related to adherence
or retention. Each clinical trial also incorporated specific
exclusion criteria. Among these, most relevant for the
current analysis were exclusion criteria for enrolment in
the hormone replacement therapy trial such as bleeding
disorders, history of pulmonary embolism or deep vein
thrombosis, current use of anticoagulants and tamoxifen,
and unwillingness to discontinue outside use of hormone
therapy (HT) at enrolment.14 All participants provided
written informed consent according to the human sub-
jects’ protection oversight at the 40 participating sites.
Recruitment (1993–1998) was conducted through mail-
ings to eligible women from large mailing lists and other
strategies. Women were followed through 2005 as part of
the original study and were offered the opportunity to
continue for an additional 5 years in the WHI extension
study. After obtaining informed consent for the extension
study, yearly questionnaires were administered by mail
between 2005 and 2010.
All participants in the clinical trials underwent a base-
line visit including physical measurements (height,
weight, blood pressure, heart rate, waist and hip circum-
ferences), blood specimen collection, a medication/sup-
plement inventory, and completion of questionnaires on
medical and family/reproductive history, lifestyle/behav-
ioural factors, and quality of life. Follow-up included a
yearly on-site clinic visit and annual mailings (a medical
history update and questionnaires about lifestyle and
dietary habits, demographics, HT, and psychosocial vari-
ables). The main outcomes of the clinical trials were cor-
onary heart disease (CHD), stroke, breast and colorectal
cancer, osteoporotic fractures and total mortality.
Assessments
Exposure
The exposure was statin use. Study participants were
instructed to bring all current medications and supple-
ments in their original containers including prescription
medications, over-the-counter medications, vitamins,
minerals and supplements to clinic for inventory at base-
line, 1-year, 3-year, 6-year and 9-year follow-up visits. The
product or generic name of the medications on the label
was entered into the database and matched to the corre-
sponding item in a pharmacy database (Master Drug
Data Base, Medi-Span, Indianapolis, Indiana, USA).
Since the prevalence of baseline statin use (7%) in the
early years of recruitment for the WHI clinical trials
(1993) was not representative of statin use during the fol-
lowing years, statin use was modelled as a time-varying
variable in the analyses; that is, USE(t)=0 when the par-
ticipant is not taking statin and USE(t)=1 once the par-
ticipant begins taking statin. Information about statin
dose (or dose of any other medication) was not available.
Antiplatelet drugs and anticoagulants
Use of these medications was assessed through a medica-
tions inventory at each planned visit as described above.
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Baseline assessments of both medications were used in
this analysis.
Outcome
Stroke was defined as the rapid onset of a persistent
neurological deficit attributable to an obstruction or
rupture of the arterial system not known to be secondary
to brain trauma, tumour, infection or other cause lasting
more than 24 h and accompanied by a lesion compatible
with acute stroke on a CT scan or MRI. Stroke was classi-
fied as ischaemic, haemorrhagic or other. Potential
strokes were identified every 6 months through self-
report from study participants or from family members
and proxies. Details regarding the illness and hospitalisa-
tions were obtained via a standardised questionnaire
administered by phone, in-person interview or self-
completed form. Next, medical records were obtained
for potential strokes, and trained physicians centrally
adjudicated all strokes requiring a hospital stay using
standard diagnostic criteria.15
Confounders
In addition to age, marital status (never, divorced or
separated, widowed, married), education (high school
or less, college or some college, postgraduate), income
(less than $20 000, $20 000–$34 999, $35 000–$49 999,
$50 000–$74 999, $75 000 or more, don’t know,
unknown) and racial/ethnic background (Caucasian,
African-American, other), we included variables that
based on the literature are associated with a higher risk
of HS.4 16 For hypertension, the available information in
the WHI data set included self-reported history of hyper-
tension as well as annual measurements of systolic and
diastolic blood pressure. Blood pressure was measured
in the right arm after participants had been seated
quietly for at least 5 min according to standard proce-
dures.17 For this analysis, hypertension was defined as
self-reported history of treated hypertension OR mea-
sured baseline blood pressure ≥140/90.17 Alcohol intake
(servings per week), history of stroke, smoking (never,
former, current)16 and history of TIA or carotid end-
arterectomy/angioplasty were assessed using self-
reported questionnaires. Waist and hip measurements
were obtained to the nearest 0.5 cm at the level of the
umbilicus and the fullest hip circumference, respectively.
Physical activity was calculated from a self-reported ques-
tionnaire as energy expenditure from recreational phys-
ical activity (total MET-hours per week).
In addition to risk factors for HS, we included covari-
ates that may lead to confounding by indication for
statin use, such as diabetes, family history of CHD, body
mass index ((weight in kilograms)/(height in metres)2
computed based on assessments of weight and height
conducted at the baseline visit) and history of cardiac
disease (a composite of previous coronary revascularisa-
tion procedures, atrial fibrillation, angina, myocardial
infarction, cardiac arrest and heart failure), all assessed
using self-reported questionnaires. Cholesterol levels
were measured in only a small group of women, and
thus we used history of elevated cholesterol needing
pharmacological treatment as a proxy. For all analyses,
we used baseline assessments of the variables listed
above.
Statistical analysis
The baseline characteristics of the study population were
computed and compared by appropriate statistical tests
(Pearson’s χ2 test for proportions and Student t test for
continuous variables) according to HS status. The associ-
ation between statins use and risk of HS was assessed
using a Cox proportional hazards regression model with
the ‘no use’ category as the reference group. Time to
event was calculated as the interval between enrolment
and the earliest of the following: date of adjudicated HS,
date of last annual medical update or death. Women in
the last two categories were censored at that date.
Women who did not consent to join the extension study
were included in the cohort and censored at the date of
last medical update or death.
The following models were generated: unadjusted;
age-adjusted; adjusted for demographics, risk factors for
HS, and enrolment status in the HT, dietary modifica-
tion and extension study (model 1); adjusted for vari-
ables included in model 1 plus variables that may lead
to confounding by indication (model 2). A subgroup
analysis was planned in women concurrently receiving
antiplatelet medications to investigate whether women
on statins and receiving concurrent treatment with these
widely used medications were at increased risk.
Results are presented as unadjusted and adjusted HRs
with 95% CIs; p values<0.05 were considered significant.
All statistical analyses were performed using SAS/STAT
V.9.3, SAS Institute, Cary, North Carolina, USA.
RESULTS
Study population
Of the original cohort of 68 132 women enrolled in the
WHI Clinical Trials, 67 882 were included in this ana-
lysis. Participants with no follow-up assessments (n=250)
were excluded from the analysis and those missing cov-
ariate information (n=9747) were excluded from multi-
variate analyses requiring that covariate. A complete-case
analysis gave substantially similar results.
Twenty-five per cent (n=17 192) of women received
statin treatment at some time during the study period.
The most commonly used statin was atorvastatin
(n=5773; 33% of statin users) followed by simvastatin
(n=4430; 25%). As for antiplatelet and anticoagulant
agents, aspirin (n=12 617, 98.5%) was most commonly
used at baseline, while only a minority of women
received dipyridamole (n=109, 1%) or ticlopidine
(n=59, 0.5%), and none received clopidogrel. Warfarin
was the most commonly prescribed anticoagulant at
baseline, however <1% of the study population was on
anticoagulants.
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Certain demographic features such as older age and
low socioeconomic status were more prevalent in women
who suffered HS during the study while there was no
association with racial/ethnic background or education
(table 1). As expected hypertension was strongly asso-
ciated with HS while we did not observe associations
with other known risk factors for HS such as smoking,
alcohol intake, physical activity and waist-to-hip ratio.
Moreover, with the exception of history of cardiac
disease, there was no association between HS and factors
that might lead to confounding by indication. Use of
anticoagulants (2.4% vs 0.6%) or antiplatelet drugs
(23% vs 19%) as well as a previous diagnosis of cerebro-
vascular disease or CHD was more prevalent among
women who suffered a HS during the study.
Main analysis
Over a mean duration of follow-up of 12 years, 421 HSs
were documented: subarachnoid haemorrhage (n=104,
25%); intracerebral haemorrhage (n=296, 70%); other
intracranial haemorrhage (n=21, 5%). The incidence
rate of HS was 6.4/10 000 person-years among women
on statins and 5.0/10 000 person-years among women
not taking statin (p=0.11). The unadjusted risk of HS
among women using statins was higher than among
those who did not (HR=1.21; CI 0.96 to 1.53; table 2
and figure 1). After adjusting for age, hypertension and
other risk factors for HS, the HR was 0.98 (CI 0.76 to
1.26). There was no evidence of confounding by indica-
tion, as variables included in model 2 did not substan-
tially modify the HR.
Subgroup analyses by use of antiplatelet drugs at base-
line indicated a higher risk of HS among women using
both statins and antiplatelet drugs compared with women
who were on antiplatelet treatment only (HR=1.59; CI 1.03
to 2.47), whereas women on statins who did not take anti-
platelet medications had no risk elevation (HR=0.80; CI
0.58 to 1.09; p for interaction=0.011, table 2 and figure 1).
The interaction term for anticoagulant use was non-
significant (p=0.72); however, given the limited number of
women on anticoagulants, the statistical power for these
analyses was low. Analyses were repeated excluding women
who were taking antiplatelet agents other than aspirin and
yielded similar results.
Post hoc analyses
To put the above findings into a risk/benefit context, we
examined whether statin treatment was associated with a
lower risk of ischaemic stroke in the overall population
and whether there was evidence for additional benefit
among women taking aspirin and statin versus statin
alone (table 3). Statin use was associated with a 14%
reduction in the risk of ischaemic stroke (HR=0.86; CI
0.74 to 0.98). Subgroup analyses by use of antiplatelet
drugs showed that women on statin and antiplatelet
medications had a lower risk of ischaemic stroke com-
pared with women on antiplatelet medications alone
(HR=0.78; CI 0.62 to 0.97), but this reduction in risk was
not significantly different from that of women on statin
alone (p for interaction=0.27).
DISCUSSION
In this large population of ageing but otherwise healthy
community-dwelling women, women who took statins at
any time during follow-up had no increase in the risk of
HS compared with women who received no statin treat-
ment after adjustment for age and known risk factors for
HS. A prespecified subgroup analysis by use of antiplate-
let drugs showed a significantly higher risk of HS among
women taking statins in association with antiplatelet
drugs (such as aspirin) compared with women taking
antiplatelet drugs alone.
Comparison with other studies
A large randomised clinical trial (40% women) found
that patients with a history of stroke within the previous
6 months treated with high-dose atorvastatin had a 66%
increase in the relative risk of HS compared with the
placebo group.8 The risk was higher among males, older
individuals and patients with a HS as the study entry
event.9 10 The risk of HS was likewise increased in a sub-
group of patients with a history of cerebrovascular disease
but no prior HS enrolled in the Heart Protection Study.12
A systematic review of the effect of statin treatment in
patients with a history of cerebrovascular disease showed
an increased risk of HS persisting even after excluding
patients with a HS as the entry event.11 The Cholesterol
Treatment Trialist (CTT) meta-analysis of large rando-
mised clinical trials of statin (or more statin) versus con-
trols (or less statin) showed that statin treatment,
compared with no statin, was associated with a non-
significant increase in the risk of HS (RR=1.15; CI 0.93 to
1.41).18 A recent meta-analysis from the same group con-
firmed a non-significant increase in the risk of HS
(HR=1.15; CI 0.97 to 1.38) per 1.0 mmol/L reduction in
LDL cholesterol among participants receiving statin treat-
ment or a higher statin dose compared with those receiv-
ing no statin or a lower statin dose.1 No subgroup analysis
by use of antiplatelet agents or anticoagulants was per-
formed in either meta-analysis. Another meta-analysis of
primary and secondary prevention trials comprehensive
of studies excluded from the CTT study found a small
non-significant excess of intracranial haemorrhage in the
statin group compared with controls (OR=1.08; 95% CI
0.88 to 1.32) and higher risk in secondary versus primary
prevention studies.19 Since the authors did not have
access to patient data, no subgroups analyses were con-
ducted by use of antiplatelet agents or oral anticoagu-
lants. In our analysis, models adjusted for demographics,
socioeconomic variables and risk factors for HS did not
show an increased risk of HS with statin use. Compared
with the large meta-analyses and the clinical trials afore-
mentioned, however, our study included an exclusively
female population and less than 3% of participants had a
history of stroke.
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Table 1 Baseline characteristics by haemorrhagic stroke
Haemorrhagic stroke
Total Yes No
p ValueCharacteristic 67,882 421 67 461
Age 62.7±7.0 66.4±7.0 62.7±7.0 <0.001
Education
≤High school diploma 16 217 113 (27.0) 16 104 (24.0) 0.297
College or some college 33 759 196 (46.8) 33 563 (50.1)
Postgraduate 17 458 110 (26.3) 17 348 (25.9)
Race
White (not of Hispanic origin) 55 368 339 (80.9) 55 029 (81.7) 0.348
Black or African-American 6959 51 (12.2) 6908 (10.3)
Other 5408 29 (6.9) 5379 (8.0)
Household income
Less than $20 000 11 345 93 (22.1) 11 252 (16.7) 0.022
$20 000–$34 999 16 392 109 (25.9) 16 283 (24.1)
$35 000–$49 999 13 435 84 (20.0) 13 351 (19.8)
$50 000–$74 999 12 428 64 (15.2) 12 364 (18.3)
$75 000 or more 10 333 47 (11.2) 10 286 (15.2)
Don’t know 1590 9 (2.1) 1581 (2.3)
Unknown 2359 15 (3.6) 2344 (3.5)
Marital status
Never married 2696 15 (3.6) 2681 (4.0) 0.004
Divorced or separated 11 008 69 (16.6) 10 939 (16.3)
Widowed 11 545 98 (23.6) 11 447 (17.0)
Presently married 42 324 234 (56.3) 42 090 (62.7)
BMI (kg/m2) 28.9±5.9 28.5±5.8 28.9±5.9 0.093
Waist-to-hip ratio 0.82±0.08 0.82±0.08 0.82±0.08 0.250
Physical activity (METs-HR/week) 10.6±12.5 10.8±14.7 10.6±12.5 0.682
Smoking status
Never-smoker 34 286 215 (51.8) 34 071 (51.1) 0.437
Past smoker 27 506 161 (38.8) 27 345 (41.0)
Current smoker 5325 39 (9.4) 5286 (7.9)
Alcohol intake (servings/week) 2.2±4.4 2.3±5.0 2.2±4.4 0.492
Cerebrovascular disease* 1825 22 (5.3) 1803 (2.7) 0.001
Previous cardiac disease† 11 502 105 (24.9) 11 397 (16.9) <0.001
Diabetes‡ 3246 21 (5.0) 3225 (4.8) 0.835
High cholesterol requiring pills 7738 58 (15.3) 7680 (12.8) 0.132
Hypertension§ 22 620 189 (49.9) 22 431 (36.8) <0.001
Family history of CHD 33 506 206 (53.7) 33 300 (52.2) 0.572
Systolic BP (mm Hg) 128.0±17.4 133.1±18.7 127.9±17.4 <0.001
Diastolic BP (mm Hg) 75.9±9.1 77.2±9.8 75.9±9.1 0.003
Antiplatelet agents¶ 12 721 96 (22.8) 12 625 (18.7) 0.032
Anticoagulants 385 10 (2.4) 375 (0.56) <0.001
Clinical trials randomisation status
Not randomised to HT trial 40 639 232 (55.1) 40 407 (59.9) 0.047
HT trial/E alone (active drug) 5283 32 (7.6) 5251 (7.8)
HT trial/E alone (placebo) 5405 49 (11.6) 5356 (7.9)
HT trial/EP (active drug) 8478 59 (14.0) 8419 (12.5)
HT trial/EP (placebo) 8077 49 (11.6) 8028 (11.9)
Not randomised to DM trial 19 227 140 (33.3) 19 087 (28.3) 0.042
DM/intervention 19 481 103 (24.5) 19 378 (28.7)
DM/control 29 174 178 (42.3) 28 996 (43.0)
Enrolment in WHI extension 52 176 256 (60.8) 51 920 (77.0) <0.001
Continuous data are expressed as mean±SD, categorical data are expressed as n (%).
p Values are student t test for continuous variables and χ2 for categorical variables.
The following variables have missing data: education (448), ethnicity (147), marital status (309), BMI (319), total MET hours/week (6401),
smoking status (765), cerebrovascular disease history (857), CHD history (20), diabetes (25), high cholesterol (7281), hypertension (6563),
systolic BP (2), diastolic BP (14), antiplatelet (1), anticoagulant (1) and family history of CHD (3706).
*Cerebrovascular disease defined as baseline self-reported history of stroke, carotid endarterectomy or TIA >6 months before enrolment.
†Previous cardiac disease defined as baseline self-reported history of coronary revascularisation procedures, atrial fibrillation, angina,
myocardial infarction (>6 months from enrolment), cardiac arrest, heart failure.
‡Diabetes defined as baseline self-reported treatment for diabetes (insulin or pills).
§Hypertension defined as baseline self-reported history of hypertension OR baseline systolic BP≥140 and diastolic ≥90.
¶Antiplatelet agents included aspirin (98.5%), dipyridamole (1%) and ticlopidine (0.5%); warfarin was the most commonly prescribed
anticoagulant (<1% of women).
BMI, body mass index; BP, blood pressure; CHD, coronary heart disease; DM, dietary modification; E, estrogen; EP, estrogen+progestin; HT,
hormone therapy; P, progestin; TIA, transient ischaemic attack; WHI, Women’s Health Initiative.
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Our findings are consistent with those of other observa-
tional studies. A meta-analysis of observational studies20
as well as a retrospective study conducted among indivi-
duals with a history of ischaemic stroke21 indicated a lack
of association between statin exposure and intracerebral
haemorrhage (RR=0.94; 95% CI 0.81 to 1.10 and
HR=0.87; 95% CI 0.65 to 1.17, respectively). In the latter
study, subgroup analyses by use of anticoagulant and anti-
platelet drugs showed a non-significant increase in the
risk of intracerebral haemorrhage with anticoagulants,
but not with antiplatelet agents use; antiplatelet agents
however did not include aspirin.
There are several possible explanations for the associ-
ation between statin treatment and increased risk of
intracerebral bleeding. First, since cholesterol plays an
important role in the integrity of the cerebral circula-
tion,22 low levels of cholesterol could potentially increase
the risk of vessel rupture. Several4–6 (but not all)23 epi-
demiological studies have in fact reported an inverse
association between plasma cholesterol levels and risk of
intracerebral haemorrhage. Second, statins have been
shown to produce antithrombotic effects:24–26 mechan-
isms could involve inhibition of platelet aggregation,
enhancing fibrinolysis, and reduced platelet expression
of the protease-activated thrombin receptor.27
Possible implications
The finding of an increased risk of HS in women using a
combination of statin and antiplatelet treatment could
have important implications for populations at higher
risk of HS. The incidence of HS in East Asian countries is
relatively higher than in Western countries with a ratio of
cerebral infarction to cerebral haemorrhage of 2:1 to 3:1,
whereas in Western countries the ratio is 5:1 to 10:1.28
This finding should also be interpreted considering the
benefits produced by statin treatment on ischaemic
stroke. Post hoc analyses indicated that statin use was asso-
ciated with a 14% reduction in the risk of ischaemic
stroke in our population, a reduction in risk that is
similar to that reported in meta-analyses of large clinical
trials conducted in predominantly male populations.1 18
We did not find evidence for an additional effect of the
combined treatment with antiplatelet agents and statins
on ischaemic stroke to counterbalance the increased risk
of HS observed with the combined treatment. The assess-
ment of the benefit of combined aspirin and statin treat-
ment on ischaemic stroke, however, was beyond the scope
of this paper. A number of studies are currently studying
the effect of the combined use of these and other medi-
cations (ie, the polypill) on cardiovascular events.29–31
Strengths and limitations
This study has a number of strengths, namely a large,
healthy, ageing female population as well as a long dur-
ation of follow-up. To the best of our knowledge, there
are no published studies assessing the risk of HS among
female statin users. Furthermore, all HSs were adjudi-
cated and statin exposure was assessed at each follow-up
visits through an inventory of all medications.
There are also several limitations, of which the most
important is the lack of measurements of LDL choles-
terol. We used baseline history of high cholesterol as a
proxy in multivariate analyses; however, adjustment for
this important confounder was not optimal. Most
Table 2 Crude and adjusted HRs of haemorrhagic stroke by statin use
Statin use*
Overall Events No (reference) Yes
p Valuen n (%) HR HR (95% CI)
Haemorrhagic stroke
Crude 67 882 421 (0.62) 1.00 1.21 (0.96 to 1.53) 0.108
Age adjusted 67 882 421 (0.62) 1.00 1.07 (0.85 to 1.35) 0.562
Model 1† 60 353 371 (0.61) 1.00 0.98 (0.76 to 1.27) 0.895
Model 2‡ 58 135 360 (0.62) 1.00 0.94 (0.70 to 1.28) 0.709
Effect modification§
Antiplatelet agents¶ 0.011
No 48 879 287 (0.59) 1.00 0.80 (0.58 to 1.09)
Yes 11 474 84 (0.73) 1.00 1.59 (1.03 to 2.47)
Anticoagulants¶ 0.719
No 60 009 361 (0.60) 1.00 0.98 (0.75 to 1.26)
Yes 344 10 (2.91) 1.00 1.24 (0.35 to 4.38)
*Statin use is modelled as time varying covariate. That is, USE(t)=0 when patient is not taking statin and USE(t)=1 once patient begins taking
statin.
†Model 1 adjusted for age, income, marital status, enrolment status in the HT, DM and extension study, baseline history of cerebrovascular
disease, hypertension, use of antiplatelet agents and anticoagulants.
‡Model 2 adjusted for variables in model 1 plus BMI, waist-to-hip ratio, physical activity, smoking status, baseline history of diabetes, baseline
history of high cholesterol requiring pharmacological treatment and baseline history of cardiac disease.
§Adjusted for same variables as model 1 and include interactions terms, statin use and antiplatelet use, statin use and anticoagulant use.
¶Antiplatelet agents included aspirin, dipyridamole and ticlopidine; anticoagulants included warfarin and heparin. See text for definitions of
each study variable.
BMI, body mass index; DM, dietary modification; HT, hormone therapy.
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importantly, we were unable to assess whether the risk of
HS was higher among women with lower LDL levels. A
second limitation was the design of this study, namely, a
retrospective, post hoc analysis conducted among
women enrolled in the WHI clinical trials. Third,
although WHI participants were recruited among
community-dwelling women, women included in this
analysis were enrolled in clinical trials and thus sub-
jected to intensive follow-up. The number of follow-up
assessments, however, was similar between women receiv-
ing statins versus women who did not (data not shown).
Fourth, despite adjustment for enrolment status in the
different clinical trials we could not eliminate selection
bias. In order to be enrolled, a series of conditions had
to be excluded, and thus our findings do not apply to
women presenting any of the exclusion criteria for par-
ticipation in the WHI clinical trials, such as bleeding dis-
orders or recent (<6 months) cardiovascular events. Our
findings are also not generalisable to younger women,
to men of any age and to non-white minorities. Fifth,
information about the intensity of statin treatment was
not collected and we were unable to determine if statins
were used for the entire interval between visits (1–3
years) and if women were compliant with their medica-
tions. Sixth, HS is a term that actually embraces different
clinical conditions, that is, among others, intracranial
haemorrhage and subarachnoid haemorrhage. We did
not have the power to assess whether statin treatment
may differentially increase the risk of each specific con-
dition. Since we did not have the power to assess effect
modification by ethnicity, these findings need further
exploration particularly among Asian women, who are at
higher risk of HS.28 Finally, while statin use was mod-
elled as a time-varying covariate, baseline assessments of
Figure 1 Adjusted HRs of haemorrhagic and ischaemic stroke
by statin use. Haemorrhagic stroke models adjusted for age,
income, marital status, enrolment status in the hormone therapy
(HT), dietary modification (DM) and extension study, baseline
history of cerebrovascular disease, hypertension, use of
antiplatelet agents and anticoagulants.
Ischaemic stroke models adjusted for age, income, marital status,
enrolment status in the HT, DM and extension study, baseline
history of cerebrovascular disease, hypertension, use of
antiplatelet agents, anticoagulants, body mass index, waist-to-hip
ratio, physical activity, smoking status, baseline history of
diabetes, and baseline history of high cholesterol requiring
pharmacological treatment and history of cardiac disease.
Table 3 Crude and adjusted HRs of ischaemic and total stroke by statin use
Statin use*
Overall Events No (reference) Yes
p Valuen n (%) HR HR (95% CI)
Ischaemic stroke
Model 1† 60 353 1643 (2.7) 1.00 0.997 (0.89 to 1.12) 0.964
Model 2‡ 58 135 1569 (2.7) 1.00 0.86 (0.74 to 0.98) 0.029
Effect modification§
Antiplatelet agents¶ 0.272
No 47 029 1144 (2.4) 1.00 0.89 (0.76 to 1.05)
Yes 11 106 425 (3.8) 1.00 0.78 (0.62 to 0.97)
Total stroke
Model 1† 60 353 2302 (3.8) 1.00 0.99 (0.90 to 1.10) 0.887
Model 2‡ 58 135 2201 (3.8) 1.00 0.86 (0.77 to 0.97) 0.016
Effect modification§
Antiplatelet use¶ 0.314
No 47 029 1623 (3.5) 1.00 0.85 (0.74 to 0.97)
Yes 11 106 578 (5.2) 1.00 0.89 (0.74 to 1.08)
See text for definitions of each study variable.
*Statin use is modelled as time varying covariate. That is, USE(t)=0 when patient is not taking statin and USE(t)=1 once patient begins taking
statin.
†Model 1 adjusted for age, income, marital status, enrolment status in the HT, DM and extension study, baseline history of cerebrovascular
disease, hypertension, use of antiplatelet agents and anticoagulants.
‡Model 2 adjusted for variables in model 1 plus BMI, waist-to-hip ratio, physical activity, smoking status, baseline history of diabetes, baseline
history of high cholesterol requiring pharmacological treatment and baseline history of cardiac disease.
§Adjusted for same variables as model 2 and include interactions terms, statin use and antiplatelet use interaction for ischaemic stroke.
¶Antiplatelet agents included aspirin, dipyridamole and ticlopidine.
BMI, body mass index; DM, dietary modification; HT, hormone therapy.
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antiplatelet and anticoagulant treatment as well as of
other variables were used in this analysis.
Conclusions and future research
Statin use was not associated with an increased risk of
HS among older community-dwelling women. A sub-
group analysis showed that treatment with statins
together with antiplatelet agents was associated with an
increased risk of HS. Owing to the observational design
of this study and the other limitations described above,
these findings need to be interpreted with caution.
Considering the widespread use of combined antiplate-
let and statin treatment for the secondary prevention of
cardiovascular events, our findings deserve further study
and replication, in particular among older women and
minorities at higher risk of HS.
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